GlassScriptPhysician profile
Leslie E Mardis
NPI 1952795361
$4,341.00
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,348 · 2022: $1,619 · 2023: $1,360 · 2024: $13.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359 · Education: $14.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.13 |
| Education | $14.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $605.24 | 2021-2023 | Reblozyl, Pomalyst |
| Amgen INC. | $490.57 | 2021-2023 | Kyprolis, Lumakras |
| Seagen INC. | $453.16 | 2021-2023 | Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $380.84 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $366.97 | 2021-2023 | Tagrisso, Enhertu, Calquence |
| Incyte Corporation | $255.03 | 2021-2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $227.65 | 2021-2023 | Opdivo, Opdualag |
| Genzyme Corporation | $184.03 | 2021-2022 | |
| Janssen Biotech, INC. | $167.01 | 2021-2023 | Darzalex |
| Eisai INC. | $120.45 | 2021-2023 | |
| Abbvie INC. | $83.39 | 2022-2024 | |
| Exelixis INC. | $83.00 | 2021-2023 | Cabometyx |
| Puma Biotechnology, INC. | $74.13 | 2021-2023 | |
| Daiichi Sankyo INC. | $73.83 | 2021-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $71.00 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $62.33 | 2023 | Fotivda |
| Beigene USA, INC. | $61.51 | 2022-2023 | Brukinsa |
| Genentech USA, INC. | $56.54 | 2021-2022 | |
| Kyowa Kirin, INC. | $54.89 | 2022-2023 | Poteligeo |
| Alexion Pharmaceuticals, INC. | $54.24 | 2021-2022 | |
| Glaxosmithkline, LLC. | $53.59 | 2022-2023 | Shingrix, Jemperli |
| Regeneron Healthcare Solutions, INC. | $48.88 | 2022 | |
| Astellas Pharma US INC | $41.21 | 2021 | |
| Epizyme, INC. | $39.60 | 2021 | |
| Mirati Therapeutics, INC. | $37.74 | 2023 | Krazati |
| Gilead Sciences, INC. | $37.14 | 2022 | |
| Acceleron Pharma, INC. | $37.01 | 2021 | |
| Sobi, INC | $23.71 | 2022 | |
| Emd Serono, INC. | $19.66 | 2023 | Bavencio |
| Adaptive Biotechnologies Corporation | $17.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.07 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $15.78 | 2022 | |
| Taiho Oncology, INC. | $14.30 | 2021 | |
| Array Biopharma INC | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Mardis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.